Filtered By:
Management: WHO
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 194 results found since Jan 2013.
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
ConclusionThis GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associated with improved clinical effectiveness in IC populations compared with BNT162b2.
Source: Frontiers in Immunology - September 12, 2023 Category: Allergy & Immunology Source Type: research
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021
MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):782-787. doi: 10.15585/mmwr.mm7229a2.ABSTRACTChronic hepatitis B virus (HBV) infection is one of the leading causes of cirrhosis and liver cancer. In 2019, approximately 1.5 million persons newly acquired chronic HBV infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR). Most chronic HBV infections are acquired through mother-to-child transmission (MTCT) or during early childhood, and approximately two thirds of these infections occur in AFR. In 2016, the World Health Assembly endorsed the goal of elimination of mother-to-child t...
Source: MMWR Morb Mortal Wkl... - July 20, 2023 Category: Epidemiology Authors: Hyacinte J Kabore Xi Li Mary M Alleman Casimir M Manzengo Mutale Mumba Joseph Biey Gilson Paluku Ado M Bwaka Benido Impouma Rania A Tohme Source Type: research
Biomimetic Nanovaccines: a Novel Approach in Immunization
Curr Pharm Des. 2023 May 29. doi: 10.2174/1381612829666230529094128. Online ahead of print.ABSTRACTAs the World Health Organization (WHO) declared, vaccines prevent an average of 2-3 million deaths yearly from diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for eradicating the deadliest diseases, viz., types of cancer, malaria, human immunodeficiency virus (HIV), and most serious microbial infections. Furthermore, scores of the existing vaccines have disadvantages, such as failure to completely stimulate the immune system, in vivo instability, high toxicity, need for the cold cha...
Source: Current Pharmaceutical Design - May 31, 2023 Category: Drugs & Pharmacology Authors: Javad Yaghmoorian Khojini Benjamin Babaei Maryam Shakarami Mahdis Mofidi Zahra Tahershamsi Tahura Fayeghi Arjmand Amir Tajbakhsh Seyed Mohammad Gheibihayat Source Type: research
Insights from establishing a high throughput viral diagnostic laboratory for SARS-CoV-2 RT-PCR testing facility: challenges and experiences
Front Public Health. 2023 Apr 17;11:1122715. doi: 10.3389/fpubh.2023.1122715. eCollection 2023.ABSTRACTBackground: The World Health Organization declared the coronavirus disease 2019 (COVID-19) a global pandemic on 11 March 2020. Identifying the infected people and isolating them was the only measure that was available to control the viral spread, as there were no standardized treatment interventions available. Various public health measures, including vaccination, have been implemented to control the spread of the virus worldwide. India, being a densely populated country, required laboratories in different zones of the co...
Source: Cancer Control - May 5, 2023 Category: Cancer & Oncology Authors: Sanchita Roy Pradhan M H Yashavarddhan Ashish Gupta Pramod Kumar Anuj Kumar Nazneen Arif Usha Agrawal R Suresh Kumar Shalini Singh Source Type: research
Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery
PLOS Glob Public Health. 2022 Apr 6;2(4):e0000101. doi: 10.1371/journal.pgph.0000101. eCollection 2022.ABSTRACTThe World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's se...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Julie Garon Carlton Joan Marembo Portia Manangazira Maxwell Rupfutse Adelaide Shearley Egnes Makwabarara Anna Hidle Anagha Loharikar Source Type: research
The Cost Analysis of Human Papillomavirus Vaccination Program in Indonesia
CONCLUSIONS: The implementation of demonstration program in Surabaya, Makassar, and Manado cities was considerably succeed. Any prediction related to the cost of implementation of HPV vaccination in Indonesia can be calculated and used to advocate regional or national government.PMID:36934486 | DOI:10.1016/j.vhri.2023.01.005
Source: Cancer Control - March 19, 2023 Category: Cancer & Oncology Authors: Didik Setiawan Andi Nurul Annisa None Lianawati Raymond C W Hutubessy Karene Hoi Ting Yeung Source Type: research
The challenge of the age of hepatitis C virus elimination: why is HCV vaccination necessary?
Orv Hetil. 2023 Mar 5;164(9):322-331. doi: 10.1556/650.2023.32737. Print 2023 Mar 5.ABSTRACTHepatitis C virus is a common cause of chronic liver disease, that may lead to cirrhosis, hepatocellular cancer and liver transplanation. The advent of highly efficacious direct-acting antivirals and their success in the treatment of hepatitis C virus infection, generated soon an optimism. Thus, the World Health Organization has adopted a global strategy of reducing the incidence of new hepatitis B and C virus infection by 90 % by 2030. However, it turned out, that this goal is not achievable by drug treatment alone without a vaccin...
Source: Orvosi Hetilap - March 5, 2023 Category: General Medicine Authors: Alajos P ár Source Type: research
